Skip to content

The effectiveness of a PRF-DRG treatment on radicular neuropathic pain

The effectiveness of a PRF-DRG treatment on radicular neuropathic pain - Effectiveness PRF-DRG

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON40047
Enrollment
46
Registered
2013-01-29
Start date
2013-03-25
Completion date
Unknown
Last updated
2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

neuralgia Radicular neuropathic pain

Interventions

None listed

Sponsors

Medisch Spectrum Twente
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: -Subjects should have lumbar of sacral radicular neuropathic pain in dermatome L4, L5 or S1 where the pain is limited for 1 dermatome for at least 3 months. The subjects should have a pain reduction of minimum 50% with a VAS score from 0 to 10 after a diagnostic block. - Subject is between 18 and 75 year - Subject has a pain score of 4 or above (visual analog scale, VAS: 0-10 from no pain to worst pain). - Subject has no new pain medication 2 weeks before the treatment. - Informed consent.

Exclusion criteria

Exclusion criteria: - Subject has sensory deficits at the QST site resulting from such medical conditions such as diabetes, alcoholic neuropathy, AIDS neuropathy, severe thyroid, liver or kidney diseases. - Former PRF and RF treatment of the same nerve root. - Subject has scar tissue, infection, or acute injury at the QST site. - Language barriers and other problems impairing the reliable completion of questionnaires. - Subject is pregnant. - Subject has a pacemaker. - Subject has a major psychiatric disease or dementia. - History of back surgery. - Other chronic pain (such as fibromyalgia). - Anticoagulation in form of vitamin K antagonists which should not be stopped. - Skin diseases (such as herpes zoster, burns etc.) - Allergy for contrast or lidocaine

Design outcomes

Primary

MeasureTime frame
Electrical sensation thresholds before and after PRF treatment

Secondary

MeasureTime frame
VAS score, symptoms of pain (pain detect), medication use, HADS and RAND-36 questionnaire

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)